Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment
US10550433B2 · kind B2 · utility
1Cited by
3References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 3, 2017 |
| Grant date | Feb 4, 2020 |
| Priority date | — |
| Expiry date | Apr 3, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.